Drug Profile
Research programme: antibody therapeutics - Millennium/UCB
Alternative Names: Antibody therapeutics research programme - Millennium/UCBLatest Information Update: 29 Jun 2006
Price :
$50
*
At a glance
- Originator Millennium Pharmaceuticals; UCB
- Class
- Mechanism of Action Chemokine receptor antagonists; T cell activation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Immunological disorders; Inflammation
Most Recent Events
- 28 Jan 2005 Preclinical trials in Immunological disorders in Europe (Injection)
- 28 Jan 2005 Preclinical trials in Immunological disorders in USA (Injection)
- 28 Jan 2005 Preclinical trials in Inflammation in Europe (Injection)